Last reviewed · How we verify
WU-NK-101
At a glance
| Generic name | WU-NK-101 |
|---|---|
| Sponsor | Wugen, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) (PHASE1)
- A Phase 1b Study of WU-NK-101 in Combination With Cetuximab (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WU-NK-101 CI brief — competitive landscape report
- WU-NK-101 updates RSS · CI watch RSS
- Wugen, Inc. portfolio CI